National Inpatient Sample, the largest publicly available inpatient care database representing more than 95% of the United States population, we extracted data using the ICD 9 code 410.7 (NSTEMI) as the primary diagnosis and the ICD 9 code 585 (CKD) as the secondary diagnosis. We excluded patients with missing information on age, sex, and mortality for a final sample size of 3,784,774. We used multilevel logistic and linear regression models with random effect to adjust for confounding. Results: Among 3,784,774 admissions for NSTEMI, 31% (1,174,006) underwent PCI. Compared to NSTEMI patients undergoing PCI with no kidney dysfunction, NSTEMI patients undergoing PCI with severe kidney dysfunction (stage 5) had a significantly longer length of stay (7.5 days vs 3.5 days, p<.0001), higher cost of hospitalization ($33,620 vs $21,477, p<.0001), greater likelihood to be discharged to a skilled nursing facility (18% vs 5%, p<.0001), greater likelihood to be on Medicare (86% vs 52%, p<.0001), and greater likelihood to be from the lowest income bracket, $0-25,000 (33% vs 27%, p<.0001). NSTEMI patients with any degree of CKD who were on Medicare had a 14% greater mortality and were 52% less likely to undergo PCI compared to NSTEMI who were self-pay (p<.0001). Women with NSTEMI with any of CKD were 25% less likely to undergo PCI compared to men with NSTEMI and any degree of CKD. Conclusion: Among NSTEMI patients undergoing PCI, increasing severity of chronic kidney disease was associated with significantly longer length of stay, higher cost of hospitalization, and a greater likelihood to be discharged to a skilled nursing facility. This subset of patients was also more likely to be of a lower income bracket and to be on Medicare. This knowledge may fuel further studies to identify tools to lessen the socioeconomic differences among NSTEMI patients with varying stages of CKD and address the disparities in utilization of advanced technology in this specific subset of patients.
CAN WE TEACH HEART FAILURE DRUGS NEW TRICKS?
245 | BEDSIDE Carvedilol vs. metoprolol tartrate on mortality in patients with heart failure with a reduced ejection fraction and atrial fibrillation or sinus rhythm: a post-hoc analysis of COMET Background: For patients with HFrEF in sinus rhythm, heart rate is a powerful prognostic marker; beta-blockers reduce heart rate and improve prognosis compared to placebo. These relationships appear disrupted for patients in atrial fibrillation (AF). We analysed data from COMET, a trial comparing carvedilol and metoprolol tartans, to explore these issues further. Purpose: To investigate the relationship between heart rate, rhythm and betablocker dose with mortality according to assigned and received treatment in the Carvedilol Or Metoprolol European Trial (COMET). Methods and results: COMET enrolled 3,029 out-patients with chronic stable heart failure; 252 had an implanted pacing device (usually a right ventricular pacemaker or ICD); of those who did not, 2209 patients were in SR at baseline, 552 in AF and 16 in undetermined rhythm. Of patients in sinus rhythm, 1360 were titrated to full doses of beta-blockers (median resting heart rate 66.0bpm (IQR: 60.0, 75.0)), of those in AF, 324 (median resting heart rate 70.0bpm (62.0, 78.8)) and of those with a device, 117 (median resting heart rate of 70.0bpm (61.0, 72.0)); 471, 111 and 58 in respectively were on study medication but not on target doses; their heart rates were 67.5bpm (60.0, 78.8), 68.0bpm (60.0, 75.0) and 72.0bpm (70.0, 80.0) respectively at the first maintenance visit. For the entire population (n=3.029), all-cause mortality was lower in patients assigned to carvedilol (hazard ratio 0·83 [95% CI 0·74-0·93], p=0·0017) and there was no significant interaction (p-value = 0.06) by the original allocated rhythm which did not account for pacing devices. In a multivariable model with predefined variables (age, sex, diabetes, ischaemic heart disease, duration of HF, NYHA, BMI, systolic blood pressure, LVEF, haemoglobin, creatinine, sodium, use of aldosterone antagonists or statins) and confined to patients taking any dose of study medication at the first maintenance visit, the hazard ratio for mortality on carvedilol compared to metoprolol was 0.86 (p-value = 0.10) for those in sinus rhythm, 0.56 (p-value = 0.001) for those in AF and for those with an implanted device 1.06 (p-value = 0.81). The interaction between treatment effect and rhythm (sinus or AF) at baseline was significant (p=0.03). Conclusions: Patients randomly assigned to and taking carvedilol had a lower mortality than those assigned to and taking metoprolol tartrate. The difference in mortality was substantially greater in patients in AF compared to sinus rhythm (after excluding patients with pacing devices). This requires further exploration. Acknowledgement/Funding: The study was supported by Roche and GSK but not this analysis. Dr Mareev is supported by an ESC Heart Failure Association Fellowship. Background: Beta-blockers improve prognosis in patients with heart failure and a reduced left ventricular ejection fraction (HFrEF) in sinus rhythm. Whether blockade of adrenergic receptors is an essential mechanism of benefit or merely one method by which to reduce heart rate is uncertain. Ivabradine also reduces heart rate but does not block adrenergic receptors. Adding ivabradine to beta-blockers reduces heart failure hospitalizations but not the risk of sudden death. However, there are few data on the effect of ivabradine on outcome in the absence of a beta-blocker.
| BEDSIDE Effect of Ivabradine on Mortality in Patients with

Methods and results:
A post-hoc analysis of the SHIFT data was conducted investigating the effect of Ivabradine on all-cause and cardiovascular mortality amongst the subgroup of patients who were not prescribed a beta-blocker. Of 6505 patients valid for this analysis, 685 (10.5%) were not taking a beta-blocker of whom 398 (58.1%) were in NYHA class III or IV and 476 (69.5%) had coronary artery disease. Their mean age was 64 (SD11) years and LVEF 29 (SD5)%.
Patients not taking beta-blockers had a mean baseline heart rate of 84 (SD12bpm), which had dropped to 68 (SD11) bpm at 28 days in those assigned to ivabradine and to 81 (SD14bpm) in those assigned to placebo. Patients assigned to placebo who were not taking beta-blockers had a higher risk profile and higher mortality (27.3%) compared to those taking beta-blockers (15.7%; p=0.009). Overall, 552 patients assigned to placebo died compared to 503 assigned to ivabradine (unadjusted HR 0.91; 95% CI 0.80-1.02; p=0.11). Amongst patients taking beta-blockers, there were 459 deaths amongst those assigned to placebo compared to 432 assigned to ivabradine (unadjusted HR 0.94; 95% CI 0.83-1.08; p=0.38). Amongst those not taking beta-blockers there were 93 deaths in those assigned to placebo but only 71 in those assigned to ivabradine (unadjusted HR 0.70; 95% CI 0.52-0.96; p=0.026). A test for interaction was of borderline significance (p=0.089). For those not taking beta-blockers there was a similar trend for cardiovascular mortality (81 versus 63 deaths; unadjusted HR 0.72 (0.52-1.00); p=0. 050). Conclusions: In SHIFT, patients who were not prescribed beta-blockers had higher heart rates and higher mortality than those prescribed beta-blockers and tended to have a greater benefit from ivabradine. This retrospective post-hoc analysis is consistent with the hypothesis that patients with HFrEF in sinus rhythm should receive a beta-blocker whenever possible but, when this is not the case, that ivabradine may reduce mortality in the absence of a beta-blocker. The strikingly similar point-estimate for the effect of beta-blockers and ivabradine "monotherapy" compared to placebo on all-cause mortality for patients with HFrEF in sinus rhythm should be explored further.
